{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:53:19Z","timestamp":1791924799263,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"DOI":"10.7759\/cureus.30035","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T13:19:42Z","timestamp":1665148782000},"source":"Crossref","is-referenced-by-count":5,"title":["Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis"],"prefix":"10.7759","author":[{"given":"Aditi V","family":"Rokade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Yelne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"What is ALS?. (2022). Accessed. July 23, 2022: https:\/\/www.als.org\/understanding-als\/what-is-als.."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/med.21528","article-title":"Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs","volume":"39","author":"Jaiswal MK","year":"2019","unstructured":"Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019, 39:733-48. 10.1002\/med.21528","journal-title":"Med Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30404-6","article-title":"Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","year":"2018","unstructured":"Global, regional, and national burden of motor neuron diseases 1990-2016. a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018, 17:1083-97. 10.1016\/S1474-4422(18)30404-6","journal-title":"Lancet Neurol"},{"key":"ref4","article-title":"Neuroanatomy, Upper Motor Neuron Lesion","author":"Emos MC","year":"2022","unstructured":"Emos MC, Agarwal S. Neuroanatomy, Upper Motor Neuron Lesion. StatPearls. Babak Abai, Amal Abu-Ghosh, Aninda B Acharya, et al. (ed): StatPearls Publishing, Treasure Island; 2022."},{"key":"ref5","unstructured":"Lower Motor Neuron - an overview | ScienceDirect Topics. (2022). Accessed. 18 july 2022: https:\/\/www.sciencedirect.com\/topics\/neuroscience\/lower-motor-neuron."},{"key":"ref6","unstructured":"What is Lou Gehrig's Disease?. (2022). Accessed. 23 july 2022: https:\/\/www.baptisthealth.com\/services\/neurology-care\/conditions\/lou-gehrigs-disease."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.007","article-title":"Amyotrophic Lateral Sclerosis: An Update for 2018","volume":"93","author":"Oskarsson B","year":"2018","unstructured":"Oskarsson B, Gendron TF, Staff NP. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018, 93:1617-28. 10.1016\/j.mayocp.2018.04.007","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldw026","article-title":"Pathogenesis of amyotrophic lateral sclerosis","volume":"119","author":"Morgan S","year":"2016","unstructured":"Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull. 2016, 119:87-98. 10.1093\/bmb\/ldw026","journal-title":"Br Med Bull"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S21981","article-title":"Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole","volume":"8","author":"Corcia P","year":"2012","unstructured":"Corcia P, Gordon PH. Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole. Ther Clin Risk Manag. 2012, 8:359-66. 10.2147\/TCRM.S21981","journal-title":"Ther Clin Risk Manag"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2014.00131","article-title":"The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis","volume":"8","author":"Pollari E","year":"2014","unstructured":"Pollari E, Goldsteins G, Bart G, Koistinaho J, Giniatullin R. The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front Cell Neurosci. 2014, 8:131. 10.3389\/fncel.2014.00131","journal-title":"Front Cell Neurosci"},{"key":"ref11","unstructured":"Clinical features of ALS - Amyotrophic Lateral Sclerosis. (2020). Accessed. 20 july 2022: https:\/\/1library.net\/article\/clinical-features-of-als-amyotrophic-lateral-sclerosis.q2p331ey."},{"key":"ref12","unstructured":"ALS Symptoms and Diagnosis. (2022). Accessed. 20 july 2022: https:\/\/www.als.org\/understanding-als\/symptoms-diagnosis."},{"key":"ref13","unstructured":"Electromyography (EMG) in the Diagnosis of ALS - ALS News Today. (2022). Accessed. 21 july 2022: https:\/\/alsnewstoday.com\/als-diagnosis\/electromyography-emg-diagnosis-als\/."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s002340050518","article-title":"MRI and clinical features in amyotrophic lateral sclerosis","volume":"39","author":"Waragai M","year":"1997","unstructured":"Waragai M. MRI and clinical features in amyotrophic lateral sclerosis. Neuroradiology. 1997, 39:847-51. 10.1007\/s002340050518","journal-title":"Neuroradiology"},{"key":"ref15","unstructured":"ALS | Diagnosing ALS Tip. Blood Tests For ALS. . (2022). Accessed: 24 july 2022: https:\/\/als.lifetips.com\/tip\/114861\/diagnosing-als\/diagnosing-als\/blood-tests-for-als.html."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2022.06.005","article-title":"Early diagnosis of amyotrophic lateral sclerosis based on fasciculations in muscle ultrasonography: A machine learning approach","volume":"140","author":"Fukushima K","year":"2022","unstructured":"Fukushima K, Takamatsu N, Yamamoto Y, et al.. Early diagnosis of amyotrophic lateral sclerosis based on fasciculations in muscle ultrasonography: A machine learning approach. Clin Neurophysiol. 2022, 140:136-44. 10.1016\/j.clinph.2022.06.005","journal-title":"Clin Neurophysiol"},{"key":"ref17","unstructured":"Amyotrophic Lateral Sclerosis (ALS) . (2015). Accessed. 22 july 2022: https:\/\/www.mda.org\/disease\/amyotrophic-lateral-sclerosis\/diagnosis."},{"key":"ref18","unstructured":"Are There Any Treatments for ALS?. (2022). Accessed. 22 july 2022: https:\/\/www.webmd.com\/brain\/understanding-als-treatment."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.20-00015","article-title":"[Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole]","volume":"140","author":"Kawano C","year":"2020","unstructured":"Kawano C, Isozaki Y, Nakagawa A, Hirayama T, Nishiyama K, Kuroyama M. [Liver Injury Risk Factors in Amyotrophic Lateral Sclerosis Patients Treated with Riluzole]. Yakugaku Zasshi. 2020, 140:923-8. 10.1248\/yakushi.20-00015","journal-title":"Yakugaku Zasshi"},{"key":"ref20","unstructured":"Riluzole Uses, Side Effects & Warnings.. (2021). Accessed. 23 july 2022: https:\/\/www.drugs.com\/mtm\/riluzole.html.."},{"key":"ref21","article-title":"Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion","volume":"24","author":"Brooks BR","year":"2018","unstructured":"Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. Am J Manag Care. 2018, 24:175-186.","journal-title":"Am J Manag Care"},{"key":"ref22","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","volume":"4","author":"Miller RG","year":"2003","unstructured":"Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003, 4:191-206.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01575.x","article-title":"Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy","volume":"14","author":"Zoccolella S","year":"2007","unstructured":"Zoccolella S, Beghi E, Palagano G, et al.. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol. 2007, 14:262-8. 10.1111\/j.1468-1331.2006.01575.x","journal-title":"Eur J Neurol"},{"key":"ref24","unstructured":"Uncovering the Benefits of Riluzole for ALS Patients. (2020). Accessed. 22 july 2022: https:\/\/alscrowd.org\/uncovering-the-benefits-of-riluzole-for-als-patients\/.."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang T","year":"2018","unstructured":"Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018, 17:416-22. 10.1016\/S1474-4422(18)30054-1","journal-title":"Lancet Neurol"},{"key":"ref26","unstructured":"Snapshot. What is Riluzole?. (2021). Accessed: 22 july 2022: http:\/\/scasource.net\/2021\/10\/15\/snapshot-what-is-riluzole\/."},{"key":"ref27","unstructured":"Edaravone Effective Regardless of Forced Vital Capacity in ALS. (2020). Accessed. 22 july 2022: https:\/\/www.neurologylive.com\/view\/edaravone-effective-regardless-of-forced-vital-capacity-in-als."},{"key":"ref28","unstructured":"Edaravone effective in small subset of ALS patients. (201`7). Accessed. 22 july 2022: https:\/\/www.consultant360.com\/story\/edaravone-effective-small-subset-als-patients."},{"key":"ref29","unstructured":"Edaravone. (2022). Accessed. 22 july 2022: https:\/\/www.drugs.com\/mtm\/edaravone.html.."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.6.2828189","article-title":"Edaravone: a new hope for deadly amyotrophic lateral sclerosis","volume":"54","author":"Bhandari R","year":"2018","unstructured":"Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018, 54:349-60. 10.1358\/dot.2018.54.6.2828189","journal-title":"Drugs Today (Barc)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02788-x","article-title":"Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study","volume":"22","author":"Park JM","year":"2022","unstructured":"Park JM, Park D, Kim HJ, Park JS. Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study. BMC Neurol. 2022, 22:260. 10.1186\/s12883-022-02788-x","journal-title":"BMC Neurol"},{"key":"ref32","article-title":"Pharmacoeconomic Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of Amyotrophic Lateral Sclerosis (ALS)","year":"2019","unstructured":"Pharmacoeconomic Review Report. Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation): Indication: For the treatment of Amyotrophic Lateral Sclerosis (ALS). Canadian Agency for Drugs and Technology in Health, Ottawa (ON); 2019."},{"key":"ref33","unstructured":"A comparison of riluzole and edaravone for the treatment of amyotrophic lateral sclerosis. (2021). Accessed. 22 july. (2022). https:\/\/open.bu.edu\/handle\/2144\/43874."},{"key":"ref34","unstructured":"Treatment and Management of Amyotrophic Lateral Sclerosis (ALS). (2022). Accessed. 24 july 2022: https:\/\/www.medindia.net\/patients\/patientinfo\/amyotrophic-lateral-sclerosis-treatment.htm."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/114619-riluzole-and-edavarone-the-hope-against-amyotrophic-lateral-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T14:50:29Z","timestamp":1707490229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/114619-riluzole-and-edavarone-the-hope-against-amyotrophic-lateral-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.30035","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}